H. Maxon

发表

Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma

P. Ladenson, V. Hertzberg, B. Haugen, 1998, Annals of Internal Medicine.

The impact of age and gender on papillary thyroid cancer survival.

J. Jonklaas, J. Robbins, P. Ladenson, 2012, The Journal of clinical endocrinology and metabolism.

Multimodality imaging of osteomyelitis

James D. Clark, H. Maxon, H. Abdel-Dayem, 1995, European Journal of Nuclear Medicine.

Dose to the liver and spleen in pediatric patients undergoing technetium-99m sulfur colloid scans.

J. Kereiakes, M. Gelfand, H. Maxon, 1979, Radiology.

Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer.

M. Sperling, H. Maxon, S. Thomas, 1993, Nuclear medicine and biology.

Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group.

M. Doody, E. Ron, S. Preston‐Martin, 1998, JAMA.

Biokinetics and dosimetry analysis in healthy volunteers for a two-injection (rest-stress) protocol of the myocardial perfusion imaging agent technetium 99m-labeled Q3

Stephen R. Thomas, H. Maxon, M. Stabin, 1995, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

B. Weintraub, P. Ladenson, M. Luster, 1999, The Journal of clinical endocrinology and metabolism.

Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.

H. Maxon, 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine.

J. Vanderheyden, H. Maxon, A. Ketring, 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Radioiodine and External Radiation Therapy in the Treatment of Thyroid Cancer

J. Brierley, H. Maxon, 1998 .

Recurrence after treatment of micropapillary thyroid cancer.

J. Jonklaas, P. Ladenson, D. Steward, 2009, Thyroid : official journal of the American Thyroid Association.

Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group.

P. Ladenson, J. Brierley, B. Haugen, 1998, Cancer.

Low Iodine Diet in I-131 Ablation of Thyroid Remnants

M. Sperling, H. Maxon, S. Thomas, 1983, Clinical nuclear medicine.

Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.

P. Ladenson, J. Brierley, B. Haugen, 1998, Thyroid : official journal of the American Thyroid Association.

Detection of residual and recurrent thyroid cancer by radionuclide imaging.

H. Maxon, 1999, Thyroid : official journal of the American Thyroid Association.

Radioiodine therapy in patients with stage I differentiated thyroid cancer.

J. Jonklaas, P. Ladenson, D. Steward, 2010, Thyroid : official journal of the American Thyroid Association.

Radiation-induced thyroid disease.

H. Maxon, 1985, The Medical clinics of North America.

Thyroid nodularity and chromosome aberrations among women in areas of high background radiation in China.

G. Beebe, A. Schneider, J. Boice, 1990, Journal of the National Cancer Institute.

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

V. Hertzberg, H. Maxon, G. J. Ehrhardt, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma.

H. Maxon, W. Mallin, A. Elgazzar, 1994, American journal of otolaryngology.

Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer.

H. Maxon, S. Thomas, R. Samaratunga, 1997, Thyroid : official journal of the American Thyroid Association.

Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.

H. Maxon, S. Thomas, S. Ali, 1988, Radiology.

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

V. Hertzberg, H. Scher, H. Maxon, 1990, Radiology.

The use of iodine as a thyroidal blocking agent in the event of a reactor accident. Report of the Environmental Hazards Committee of the American Thyroid Association.

L. Braverman, A. Schneider, C. Gorman, 1984, JAMA.

I‐123 MIBG Scintigraphy in Adults A Report of Clinical Experience

James D. Clark, M. Gelfand, H. Maxon, 1995, Clinical nuclear medicine.

Age-, sex-, and race-related differences in myoglobin concentrations in the serum of healthy persons.

E. Stein, M. Sperling, H. Maxon, 1980, Clinical chemistry.

Nonspecific binding as a source of error in thyrotropin radioimmunoassay with polyethylene glycol as separating agent.

H. Maxon, J. Tsay, I. Chen, 1980, Clinical chemistry.

Nonspecific Bindingas a Source of Error in ThyrotropinRadioimmunoassay with PolyethyleneGlycol as SeparatingAgent

H. Maxon, Y. Tsay, L. Heminger, 1980 .

A commercial digoxin radioassay modified for use as an emergency ("stat") procedure.

M. Sperling, H. Maxon, I. Chen, 1979, Clinical chemistry.

Blunted growth hormone (GH) response to GH-releasing hormone in hypothyroidism resolves in the euthyroid state.

L. Frohman, M. Thorner, H. Maxon, 1985, The Journal of clinical endocrinology and metabolism.

Production and Application of 123I-Labeled M-Iodobenzylguanidine (123I-MIBG)

M. Gelfand, H. Maxon, L. Washburn, 1995 .

Long-term observations of glucose tolerance in thyrotoxic patients.

H. Maxon, R. Goldsmith, H. Knowles, 1975, Archives of internal medicine.

Semiautomated system for simultaneous assays of serum vitamin B12 and folic acid in serum evaluated.

H. Maxon, E. Silberstein, I. Chen, 1982, Clinical chemistry.

A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP.

M. Sperling, H. Maxon, S. Thomas, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Rhenium-188(Sn)HEDP for treatment of osseous metastases.

H. Maxon, G. J. Ehrhardt, S. Thomas, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A statistical method for determining normal ranges from laboratory data including values below the minimum detectable value.

H. Maxon, J. Tsay, I. Chen, 1979, Clinical chemistry.

Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases.

V. Hertzberg, H. Scher, H. Maxon, 1992, Seminars in nuclear medicine.

Clinically important radiation-associated thyroid disease. A controlled study.

J. Kereiakes, H. Maxon, S. Thomas, 1980, JAMA.

Ionizing irradiation and the induction of clinically significant disease in the human thyroid gland.

J. Kereiakes, H. Maxon, S. Thomas, 1977, The American journal of medicine.

Clinical comparison of technetium-99m diphosphonate and pyrophosphate in bone scintigraphy: concise communication.

G. Bahr, H. Maxon, E. Silberstein, 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Stability of immunologic activity of human prostatic acid phosphatase in serum.

L. Kaplan, M. Sperling, H. Maxon, 1982, Clinical chemistry.

Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

V S Hertzberg, J G Kereiakes, E L Saenger, 1983, The New England journal of medicine.

Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer.

J G Kereiakes, E L Saenger, J. Kereiakes, 1977, Radiology.

Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.

Howard S. Smith, H. Maxon, H. Smith, 1990, Endocrinology and metabolism clinics of North America.

Iodine 131 uptake by primary lung adenocarcinoma. Misinterpretation of 131I scan.

H. Maxon, M. Fernández-Ulloa, L. Sholiton, 1976, JAMA.

Cancer Mortality Following Treatment for Adult Hyperthyroidism

M. Doody, E. Ron, S. Preston‐Martin, 1998 .

Evaluation and comparison of radio-, fluorescence, and enzyme-linked immunoassays for serum thyroxine.

L. Kaplan, E. Stein, H. Maxon, 1981, Clinical biochemistry.

Radionuclide and Iothalamate Meglumine Roentgenographic Arthrography in the Evaluation of Painful Total Hip Arthroplasty

J. Kereiakes, C. Hopson, Diane, 2005 .

A comparative study of indium-111 DTPA radionuclide and iothalamate meglumine roentgenographic arthrography in the evaluation of painful total hip arthroplasty.

J. Kereiakes, C. Hopson, H. Maxon, 1989, Clinical orthopaedics and related research.

Prospective multicenter study of thyroid carcinoma treatment

P. Ladenson, J. Brierley, B. Haugen, 1998 .

Outcomes of patients with differentiated thyroid carcinoma following initial therapy.

J. Jonklaas, P. Ladenson, J. Brierley, 2006, Thyroid : official journal of the American Thyroid Association.

Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

J. Jonklaas, P. Ladenson, D. Steward, 2015, The Journal of clinical endocrinology and metabolism.

Metastatic pulmonary calcification in primary hyperparathyroidism.

W. Altemeier, H. Maxon, R. Loudon, 1977, Archives of internal medicine.

Dose to the metaphyseal growth complexes in children undergoing 99mTc-EHDP bone scans.

V. J. Sodd, P. A. Feller, J. Kereiakes, 1978, Radiology.

The Role of Medical Imaging in the Diagnosis and Follow-Up of Recurrent or Metastatic Thyroid Cancer

H. Maxon, K. Choe, 1998 .

Sensitivity test of perfusion lung images: lateral views vs oblique views.

H. Maxon, E. Silberstein, H. Nishiyama, 1976, International journal of nuclear medicine and biology.

Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.

V S Hertzberg, Michael D. Aden, V. Hertzberg, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Role of Nuclear Medicine in the Treatment of Hyperthyroidism and Well‐Differentiated Thyroid Adenocarcinoma

H. Maxon, S. Thomas, I. Chen, 1981, Clinical nuclear medicine.

Hypercalcemia in thyrotoxicosis.

D. Apple, H. Maxon, R. Goldsmith, 1978, Surgery, gynecology & obstetrics.

Reliable preparation of 99mTc (V) DMSA by a simple modified method using a commercial kit for 99mTc (III) DMSA.

H. Maxon, D. Biniakiewicz, L. Washburn, 1995, Nuclear medicine and biology.

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

J. Jonklaas, P. Ladenson, D. Steward, 2014, Thyroid : official journal of the American Thyroid Association.

In vivo quantitation of lesion radioactivity using external counting methods.

J G Kereiakes, J. Kereiakes, H. Maxon, 1976, Medical physics.

Diagnostic specificity of serum myoglobin radioimmunoassay for acute myocardial infarction is improved by using age-, sex-, and race-specific reference ranges.

E. Stein, M. Sperling, H. Maxon, 1982, Clinical chemistry.

A StatisticalMethodfor DeterminingNormalRangesfrom LaboratoryData IncludingValues below the MinimumDetectable Value

H. Maxon, J. Tsay, L. Heminger, 2004 .

A Statistical Method forDetermining NormalRangesfrom Laboratory DataIncluding ValuesbelowtheMinimum Detectable Value

H. Maxon, 1979 .

Safety and Efficacy of Repeated Sequential Administrations of Re-186(Sn)HEDP as Palliative Therapy for Painful Skeletal Metastases: Initial Case Reports of Two Patients

Stephen R. Thomas, H. Maxon, E. Englaro, 1992, Clinical Nuclear Medicine.

Familial elevations of total and free thyroxine in healthy, euthyroid subjects without detectable binding protein abnormalities.

A. Burger, K. Burman, H. Maxon, 1982, Acta endocrinologica.

Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine.

W. Ritschel, H. Maxon, M. Eldon, 1983, International journal of clinical pharmacology, therapy, and toxicology.

Variations in Serum Thyroxine Concentrations with Time after an Oral Replacement Dose

V. Hertzberg, H. Maxon, I. Chen, 1987, Clinical nuclear medicine.

Potential Errors Caused by Variable Radionuclidic Purity of Iodine-123

Stephen R. Thomas, H. Maxon, W. J. Love, 1979 .

Radiation absorbed-dose estimates for the liver, spleen, and metaphyseal growth complexes in children undergoing gallium-67 citrate scanning.

J. Kereiakes, M. Gelfand, H. Maxon, 1983, Radiology.

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.

J. Jonklaas, P. Ladenson, D. Steward, 2015, Thyroid.

Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

J. Garber, F. Wondisford, F. Brucker-Davis, 1997, The New England journal of medicine.

Clinical significance of serum vitamin B12 measured by radioassay using pure intrinsic factor.

M. Sperling, H. Maxon, E. Silberstein, 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiation-Associated Carcinoma of the Salivary Glands a Controlled Study

J. Kereiakes, H. Maxon, C. Buncher, 1981, The Annals of otology, rhinology, and laryngology.

Emergency procedure for digoxin radioassay.

M. Sperling, H. Maxon, I. Chen, 1978, Clinical chemistry.

Procainamide induced systemic lupus erythematosus.

D. Zipes, H. Maxon, 1971, Military medicine.